Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VRTX vs DXCM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXCM Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 4–6 Matrix Metrics)

DXCM Overall Winner 6-Pillar Tally: VRTX 2 – 4 DXCM Matrix Metrics: VRTX 6 – 4 DXCM

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Vertex Pharmaceuticals Inc (VRTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). VRTX carries a Unified Composite Score of 40.9/100 (SELL) at $515.02 (25.9x Forward P/E, 37.8% operating margin), whereas DXCM carries 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin).

  • Technical & Structure Timing Caution: VRTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.9); meanwhile DXCM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VRTX vs DXCM
VRTX NASDAQ
Vertex Pharmaceuticals Inc
Pharmaceutical Preparations
$515.02
-1.08% 1D
Market Cap $132.0B
TTM Revenue $13.0B
Forward P/E 25.9x
Beta / 30D Vol 0.35β · 28% Vol
Unified Composite Score
40.9 / 100 SELL
Tech 25.0 Fund 47.0 Flow 69.0 Mom 46.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope 0.0%) with fading momentum, RSI 41
RSI-14: 40.9 · SMA20: $538.04 · SMA50: $522.73
DXCM NASDAQ Head-to-Head Winner
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap $29.9B
TTM Revenue $5.10B
Forward P/E 25.3x
Beta / 30D Vol 0.59β · 43% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $81.49 · SMA50: $83.94

6-Pillar Scorecard Institutional Category Breakdown (VRTX 2 – 4 DXCM)

Columns: Metric · VRTX · DXCM
1. Valuation Multiples DXCM
Forward P/E 25.9x 25.3x
Trailing P/E 33.5x 31.6x
PEG Ratio 2.34x 1.30x
EV / Revenue 10.3x 5.9x
2. Growth & Scale VRTX
Revenue Growth (YoY) +11.8% +11.2%
Earnings Growth (YoY) -39.0% +2.6%
TTM Revenue (USD) $13.0B $5.10B
Market Cap $132.0B $29.9B
3. Profitability & Quality VRTX
Gross Margin 54.8% 63.4%
Operating Margin 37.8% 24.0%
Net Profit Margin 30.7% 19.4%
Return on Equity (ROE) 20.8% 37.7%
4. Balance Sheet & Cash Flow DXCM
Cash Generation (TTM) $3.20B $1.73B
Cash Flow Margin 24.7% 33.9%
Net Cash / Leverage $1.50B Net Debt (0.31x D/E) $432M Net Debt (0.55x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DXCM
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 115.6% (33rd %ile) 63.0% (15th %ile)
Put/Call OI Skew 1.00x (Balanced) 0.48x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Distribution ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat DXCM
OpEx & R&D Intensity 17.0% of Rev ($2.20B) 39.4% of Rev ($2.01B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VRTX (6) vs DXCM (4)
Institutional Metric VRTX DXCM Criterion Row Edge
Market Capitalization
Scale
$132.0B $29.9B Larger Scale VRTX
Trailing P/E Ratio
Valuation
33.5x 31.6x Lower Multiple DXCM
Forward P/E Ratio
Valuation
25.9x 25.3x Lower Multiple DXCM
Revenue Growth (YoY)
Growth
+11.8% +11.2% Higher Growth VRTX
Operating Margin (TTM)
Profitability
37.8% 24.0% Higher Margin VRTX
Net Profit Margin
Profitability
30.7% 19.4% Higher Margin VRTX
Return on Equity (ROE)
Capital Efficiency
20.8% 37.7% Higher ROE DXCM
52-Week Range Position
Momentum
66% ($412–$569) 63% ($57–$93) Stronger Trend VRTX
Beta / 30D Volatility
Risk Regime
0.35β · 28% Vol 0.59β · 43% Vol Lower Realized Risk VRTX
Unified Institutional Score
Composite Signal
40.9 / 100 (SELL) 50.8 / 100 (HOLD) Higher Composite DXCM
Trailing 12M Revenue (USD)
Operating Scale
$13.0B $5.10B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
54.8% 63.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.34x PEG · 10.3x EV/Rev 1.30x PEG · 5.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.20B ($1.50B Net Debt (0.31x D/E)) $1.73B ($432M Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DXCM +5.05 pp
VRTX: -3.77% · DXCM: +1.28%
3M Horizon VRTX +6.94 pp
VRTX: -5.95% · DXCM: -12.89%
6M Horizon VRTX +8.52 pp
VRTX: +18.53% · DXCM: +10.01%
1Y Horizon DXCM +10.48 pp
VRTX: +22.32% · DXCM: +32.8%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VRTX Revenue DXCM Revenue VRTX Op. Margin DXCM Op. Margin Margin Leader
FY2018 $3.05B $1.03B 20.8% -18.1% VRTX
FY2019 $4.16B $1.48B 28.8% 9.6% VRTX
FY2020 $6.21B $1.93B 46.0% 15.5% VRTX
FY2021 $7.57B $2.45B 36.7% 10.9% VRTX
FY2022 $8.93B $2.91B 48.2% 13.4% VRTX
FY2023 $9.87B $3.62B 38.8% 16.5% VRTX
FY2024 $11.0B $4.03B -2.1% 14.9% DXCM
FY2025 $12.0B $4.66B 34.8% 19.6% VRTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VRTX CONSOLIDATION
62d in phase · OBV DISTRIBUTION
Current IV 115.6%
IV Percentile 33rd %ile
Put/Call OI Skew 1.00x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact VRTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DXCM CONSOLIDATION
73d in phase · OBV ACCUMULATION
Current IV 63.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.48x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $537.79 · IV 35.9%

VRTX vs. DXCM: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of VRTX ($53,779) vs. DXCM ($8,161) against risk-defined 5-day vertical and put-wall option structures.

VRTX Spot $537.79 · IV 35.9%
VRTX Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $540 / $570 Bull Call Spread

Buy 1x $540C · Sell 1x $570C · 31d

Net Entry $1,114 Debit
T+5d @ +5% Move +$591 (+53%)
Max Risk / Buffer $1,114 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $500 / $470 Bull Put Spread

Sell 1x $500P · Buy 1x $470P · 31d

Net Entry $545 Credit
Max Credit / Yield +$545 (+22.2% RoM)
Max Risk / Buffer -8.0% Cushion ($2,455 Mgn)
5d Edge & Liquidity 77% PoP · Liq A
Simulate 5-Day Payoff →
DXCM Spot $81.61 · IV 39.6%
DXCM Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $80 / $90 Bull Call Spread

Buy 1x $80C · Sell 1x $90C · 31d

Net Entry $482 Debit
T+5d @ +5% Move +$136 (+28%)
Max Risk / Buffer $482 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $75 / $70 Bull Put Spread

Sell 1x $75P · Buy 1x $70P · 31d

Net Entry $86 Credit
Max Credit / Yield +$86 (+20.8% RoM)
Max Risk / Buffer -9.2% Cushion ($414 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VRTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $132.0B market capitalization and 37.8% operating margin.
OpEx & R&D Reinvestment 17.0% of Rev ($2.20B)
90D Engineering Disclosures 0 Published
DXCM Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 39.4% of Rev ($2.01B)
90D Engineering Disclosures 0 Published

Investor FAQ VRTX vs DXCM Key Questions & Quantitative Answers

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Vertex Pharmaceuticals Inc (VRTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). VRTX carries a Unified Composite Score of 40.9/100 (SELL) at $515.02 (25.9x Forward P/E, 37.8% operating margin), whereas DXCM carries 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin). Technical & Structure Timing Caution: VRTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.9); meanwhile DXCM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VRTX leads the Growth & Scale pillar: VRTX posts +11.8% YoY revenue growth and -39.0% YoY earnings growth on $13.0B TTM revenue (54.8% gross margin, 37.8% operating margin), compared with DXCM at +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VRTX cumulative revenue shifted +293.4% while DXCM shifted +352.4%. In operating R&D and SG&A reinvestment, VRTX deploys 17.0% of Rev ($2.20B) (0 90-day corporate R&D disclosures) versus 39.4% of Rev ($2.01B) (0 disclosures) for DXCM.

DXCM screens cheaper on headline valuation multiples. VRTX trades at 25.9x Forward P/E, 33.5x Trailing P/E, 2.34x PEG, and 10.3x EV/Revenue (24.7% FCF margin), whereas DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRTX (20.8% ROE) versus DXCM (37.7% ROE) capital efficiency.

In options market volatility and institutional positioning, VRTX carries 115.6% implied volatility (33rd %ile, Balanced (25th–60th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.35β · 28% Vol realized risk). By comparison, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.